title: Antitumoral effects of lipopolysaccharides, tumor necrosis factor, interferon and activated macrophages: synergism and tissue distribution.
abstract: Treatment of C57BL/6 mice bearing Lewis lung carcinoma or of BALB/c mice bearing EMT6 sarcoma with tumor necrosis factor (TNF), lipopolysaccharides (LPS) or interferon caused necrosis of the solid tumors and regression. Toxicity was observed in tumor-bearing animals when TNF or LPS were used at effective antitumoral doses. Similar antitumoral effects could be achieved using less than 1 million macrophages from C57BL/6, lung of from BALB/c peritoneal cavity expanded in vitro, and spontaneously fully activated to cytotoxicity during culture. This effect, observed after transfer twice a week by intravenous or peritumoral route, was not dependent on histocompatibility. Additive effects were observed after combined treatment with activated macrophages and a low dose of LPS or TNF. The biodistribution of labelled LPS and of labelled cytotoxic macrophages was studied in tumor-bearing mice. Although, as expected, LPS was concentrated essentially in the liver, a slow accumulation in the center of the tumor was observed. Macrophages injected intravenously accumulated in the lung and were then redistributed towards liver, kidney and the tumor periphery. Macrophages injected locally remained essentially in the tumor periphery with a slow redistribution in the body. The complementary localization of LPS and of cytotoxic macrophages respectively in the center and periphery of solid tumors might explain their synergism.
authors.affiliation: Department d'Immunologie et d'Immunopharmacologie, UER Pharma, Illkirch, France.
authors.forename: M
authors.initials: M
authors.lastname: Chokri
authors.forename: M
authors.initials: M
authors.lastname: Freudenberg
authors.forename: C
authors.initials: C
authors.lastname: Galanos
authors.forename: P
authors.initials: P
authors.lastname: Poindron
authors.forename: J
authors.initials: J
authors.lastname: Bartholeyns
mesh_terms: D000818:Animals; D002478:Cells, Cultured; D005260:Female; D007167:Immunotherapy; D007370:Interferon Type I / Q000627:therapeutic use*; D008070:Lipopolysaccharides / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy / Q000628:therapy*; D008262:Macrophage Activation; D008264:Macrophages / Q000276:immunology / Q000637:transplantation*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D011994:Recombinant Proteins; D012513:Sarcoma, Experimental / Q000188:drug therapy / Q000628:therapy*; D013045:Species Specificity; D014018:Tissue Distribution; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use*
chemical_list: D007370:Interferon Type I; D008070:Lipopolysaccharides; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha